Boston Scientific sees sales increases in 1999
Interventional medical device manufacturer Boston Scientific reported healthy results for fourth quarter and fiscal 1999 (end-December). The Natick, MA, company posted net sales for the quarter of $717 million, flat with sales for the same period in
Interventional medical device manufacturer Boston Scientific reported healthy results for fourth quarter and fiscal 1999 (end-December). The Natick, MA, company posted net sales for the quarter of $717 million, flat with sales for the same period in 1998. Net income was $107 million, up from $71 million the previous year. For the year, the company saw a 27% increase in net sales, from $2.2 billion in 1998 to $2.8 billion in 1999. Net income for the year was $371 million. Excluding charges and credits related to the companys acquisition activity, net income rose 39%, from 1998s $262 million to $364 million.
Boston Scientific attributed its increased income in part to the completion of its acquisition of Schneider Worldwide, a division of Pfizers Medical Technology Group, which the company agreed to purchase in 1998 for $2.1 billion in cash (SCAN 6/24/98). Schneider operates out of Bulach, Switzerland, and manufactures stents and angioplasty devices and accessories. With Schneider under its corporate umbrella, Boston Scientific has gained access to high-growth areas of interventional medicine products, including rapid-exchange catheters and nylon balloon technology.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
